yahoo_financeOriginal article
Novartis Says Cosentyx Shows Sustained Remission in Phase 3 Trial
Phase 3positiveCosentyxPositive
AI Analysis
Summary
Novartis announced that Cosentyx demonstrated sustained remission in a Phase 3 trial, indicating a positive clinical outcome for the drug candidate.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Sustained remission demonstrated
Importance:7/10
Sentiment:
0.70
Phase 3trial resultsCosentyxremission
Related Companies
Read the original article
Published by yahoo_finance on June 3, 2026 6:32 PM